Company reiterates focus on advancing ProLectin‑M under an active FDA IND and progressing oxygen-transport programs for stroke and neurodegenerative diseases NEEDHAM, Mass., January 29, 2026...
Summary: Progress in Neurodegenerative Research: NKGen’s Phase 1/2a Clinical Trial for SNK01 on Track for End-of-Year Initiation SANTA ANA, Calif., Oct. 24, 2023 (Plato /...
